长期服用他汀类药物的代谢综合征患者的运动训练适应
研究纳入106例代谢综合征患者,分为他汀组(n=46)与未用他汀的对照组(n=60),完成16周高强度间歇训练(HIIT)。他汀使用未妨碍代谢综合征组分、最大脂肪氧化及肌肉线粒体酶(CS、HAD)的改善,但他汀组VO2PEAK改善幅度低于对照组。
要点
- 他汀组与对照组HIIT后代谢综合征z评分变化分别为-0.26±0.38与-0.22±0.31,组间交互P=0.60。
- 16周HIIT后两组HAD活性与FOMAX均升高(时间效应P<0.03)。
- 他汀组VO2PEAK改善12%,对照组19%(时间×组别效应P=0.013)。
核心结论
- 代谢综合征患者长期使用他汀不干扰运动训练对代谢综合征组分、FOMAX及肌肉线粒体酶(即CS和HAD)的改善,但他汀组减弱了训练对VO2PEAK的改善。
研究设计与样本
- 研究共纳入106例代谢综合征患者,分为他汀使用者(他汀组,n=46)与未使用他汀者(对照组,n=60),两组按年龄、体重及代谢综合征组分匹配。
- 受试者完成16周高强度间歇训练(HIIT),训练前后采集肌肉活检评估线粒体含量(柠檬酸合酶[CS]活性)与限速β氧化酶(3-羟酰辅酶A脱氢酶[HAD])活性,并测定空腹血糖、胰岛素、TG、HDL-c、LDL-c、运动最大脂肪氧化(FOMAX)与摄氧峰值(VO2PEAK)。
- 临床试验注册号ClinicalTrials.gov NCT03019796,注册日期2017年1月13日。
主要发现
- 训练对两组代谢综合征的改善相似(代谢综合征z评分-0.26±0.38 vs -0.22±0.31;时间效应P<0.001,时间×组别效应P=0.60)。
- 训练前他汀组肌肉HAD活性与全身FOMAX低于对照组;16周HIIT后两组HAD与FOMAX均升高(时间效应P<0.03)。
- 他汀组未阻止对照组中HIIT引起的CS升高(他汀组38% vs 对照组64%;时间效应P<0.001)。
- 训练后他汀组VO2PEAK改善低于对照组(他汀组12% vs 对照组19%;时间×组别效应P=0.013)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins reduce atherogenic dyslipidemia and cardiovascular disease (CVD) risk in metabolic syndrome (MetS) individuals. Exercise training could also contribute to reduce CVD by improving cardiorespiratory fitness and fat oxidation. However, statin use could interfere with training adaptations. METHODS: A total of 106 MetS individuals were divided into statin users (statin group, n = 46) and statin-naïve (control group, n = 60). Groups were matched by age, weight, and MetS components. Subjects completed 16 weeks of high intensity interval training (HIIT). Before and after HIIT, muscle biopsies were collected to assess mitochondrial content (citrate synthase [CS] activity) and the activity of the rate limiting β-oxidation enzyme (3-hydroxyacyl-CoA-dehydrogenase [HAD]). Fasting plasma glucose, insulin, TG, HDL-c, and LDL-c concentrations were measured. Exercise maximal fat oxidation (FOMAX) and oxygen uptake (VO2PEAK) were determined. RESULTS: Training improved MetS similarly in both groups (MetS z-score -0.26 ± 0.38 vs. -0.22 ± 0.31; P < 0.001 for time and P = 0.60 for time x group). Before training, the statin group had reduced muscle HAD activity and whole body FOMAX compared to the control group. However, 16 weeks of HIIT increased HAD and FOMAX in both groups (P < 0.03, time-effect). The statin group did not prevent the increases in CS with HIIT observed in the control group (38% vs 64%, respectively; P < 0.001, time-effect). Conversely, with training VO2PEAK improved less in the statin than in the control group (12% vs. 19%, respectively; P = 0.013, time × group effect). CONCLUSION: Chronic statin use in MetS does not interfere with exercise training improvements in MetS components, FOMAX, or mitochondrial muscle enzymes (ie, CS and HAD). However, the statin group attenuated the improvements in VO2PEAK with training. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov identifier no. NCT03019796, January 13, 2017.
引用
- Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, et al. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. J Clin Endocrinol Metab. 2020. PMID: 31875915. doi:10.1210/clinem/dgz304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。